Trial intelligence / Profile preview

Exploratory randomized trial of M0003 for PPI-refractory GERD

2010-021397-12Phase 2Completed

Sponsor: Movetis
Start: Sep 2010
Countries: 1

Overview

Phase 2, randomised, double-blind trial in gastroesophageal reflux disease (GERD) comparing M0003 with Placebo (2 arms). Primary endpoint: Exploratory pharmacodynamic effect on reflux parameters. Started Sep 2010; status: completed.

Drugs

M0003

Conditions

gastroesophageal reflux disease (GERD)

Beyond the preview

Go deeper on 2010-021397-12.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2010-021397-12.